AIMD
Ainos, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.60
+2.56%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 13.6K | 124.2K | 20.7K | 122.1K | 3.5M |
| Cost of Revenue | 4.8M | 4.8M | 52.6K | 375.8K | 2.1M |
| Gross Profit | (4.8M) | (4.7M) | (31.9K) | (253.7K) | 1.4M |
| Operating Expenses | |||||
| R&D Expense | 6.5M | 7.7M | 8.4M | 7.3M | 6.8M |
| SG&A Expense | 2.5M | 1.6M | 5.4M | 5.6M | 8.5M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.00 | — | — | — | — |
| Total Operating Expenses | 9.0M | 9.3M | 13.8M | 13.0M | 15.4M |
| Cost and Expenses | 13.8M | 14.1M | 13.9M | 13.3M | 17.5M |
| Operating Income (EBIT) | (13.8M) | (14.0M) | (13.8M) | (13.2M) | (14.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 730.5K | 711.9K | 616.5K | 144.2K | 53.5K |
| Net Interest Income | (730.5K) | (711.9K) | (616.5K) | (144.2K) | (53.5K) |
| Other Non-Op Income/Expense | (689.1K) | (779.8K) | (1.0M) | (563.4K) | (30.5K) |
| Non-Operating Income (excl Interest) | (36.9K) | 67.9K | 404.7K | 419.2K | (23.1K) |
| EBT (Pre-Tax Income) | (14.5M) | (14.8M) | (14.9M) | (13.8M) | (14.0M) |
| Income Tax Expense | 800.00 | 800.00 | 800.00 | 800.00 | — |
| Bottom Line | |||||
| Net Income | (14.5M) | (14.8M) | (14.9M) | (13.8M) | (14.0M) |
| Earnings from Cont. Ops | (14.5M) | (14.8M) | (14.9M) | (13.8M) | (14.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (14.5M) | (14.8M) | (14.9M) | (13.8M) | (14.0M) |
| Per Share | |||||
| Basic EPS | ($2.52) | ($3.46) | ($1.56) | ($3.36) | ($5.14) |
| Diluted EPS | ($2.52) | ($3.46) | ($1.56) | ($3.36) | ($5.14) |
| Revenue Per Share | $0.00 | $0.03 | $0.00 | $0.03 | $1.29 |
| Shares | |||||
| Basic Shares Outstanding | 7.4M | 4.3M | 9.5M | 4.1M | 2.7M |
| Diluted Shares Outstanding | 7.4M | 4.3M | 9.5M | 4.1M | 2.7M |
| Profitability Metrics | |||||
| EBITDA | (9.0M) | (9.3M) | (9.4M) | (8.8M) | (9.1M) |
| D&A | 4.8M | 4.8M | 4.8M | 4.9M | 4.8M |
| EBIT | (13.7M) | (14.1M) | (14.2M) | (13.6M) | (14.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026